Resynthia: Allogenic Tissue Synthesis
Resynthia: Allogenic Tissue Synthesis
  • Home
  • Pipeline
  • Team
  • Contact Us
  • More
    • Home
    • Pipeline
    • Team
    • Contact Us
  • Sign In
  • Create Account

  • Orders
  • My Account
  • Signed in as:

  • filler@godaddy.com


  • Orders
  • My Account
  • Sign out


Signed in as:

filler@godaddy.com

  • Home
  • Pipeline
  • Team
  • Contact Us

Account


  • Orders
  • My Account
  • Sign out


  • Sign In
  • Orders
  • My Account

TEAM

Jonathan Ward MBA

Co-founder & CEO

Jonathan  Ward has more than 20 years experience in preclinical R&D and  toxicology testing. Jonathan was the COO at PWG Genetics (preclinical   CRO) and Bioresearch Manager and Principal Scientist at Philip Morris  International (leading toxicology studies as Test Facility Manager).

Jaya Krishnan PhD

Co-founder & CTO

Prof.  Jaya Krishnan has more than 20 years experience in preclinical models  and cardiovascular disease research. He completed his PhD at Imperial   College London and led research at the ETH-Zurich, Medical Research  Council UK and Imperial College London. He currently leads an RNA  Therapeutics group in Germany.

Pham Minh Duc DBiol

Co-founder & Head of Development

Duc Minh Pham has more than 10 years of experience in assay development, human pluripotent stem cells and organoid culture in Albert-Ludwigs University Hospital Freiburg and Goethe University Hospital Frankfurt. His work  is focused on generating/validating heart and lung organoid models for biomedical research, and drug discovery and development.

Maria Duda PhD

Chief Operating Officer

Dr.  Maria Duda joins Genome Biologics from Management Consulting company ZS  Associates where she assessed and developed strategies in the area of   key account management and launch planning for top pharmaceutical  clients. Prior to career in Management Consulting, Maria led a  multi-disciplinary project at Medical Research Council UK aimed at   understanding the mechanical underpinnings of disease. Maria received  her scientific training from ETH Zurich, where she obtained her PhD in  novel therapeutic approaches for kidney cancer.

Copyright © 2021 Resynthia - All Rights Reserved.

  • Privacy Policy
  • Terms and Conditions